MAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and ...

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer ...

(NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted ...

MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In ...

MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company, has announced a private placement agreement ...

Earnings Estimate Revisions for MAIA Biotechnology, Inc. This company is expected to earn -$0.75 per share for the fiscal year ending December 2025, which represents no year-over-year change ...

MAIA Biotechnology (NYSE:MAIA), a small ($20 million) 2022 biotech IPO, has reported encouraging preliminary Phase 2 data in NSCLC that suggests its lead asset, THIO, could represent a fundamental ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing ...

MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today ...

MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on ...